Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
18.29
+0.49 (2.75%)
Apr 17, 2025, 4:00 PM EDT - Market closed

Celldex Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-157.86-141.43-112.33-70.51-59.78
Upgrade
Depreciation & Amortization
3.183.012.93.073.93
Upgrade
Loss (Gain) From Sale of Assets
0.02-0-0.02-0.06
Upgrade
Asset Writedown & Restructuring Costs
---3.518
Upgrade
Loss (Gain) From Sale of Investments
-15.75-6.220.84-3.21-0.73
Upgrade
Stock-Based Compensation
34.2423.8915.618.953.92
Upgrade
Other Operating Activities
---6.86-1.63-5.39
Upgrade
Change in Accounts Receivable
1.93-2.28-0.181.57-0.79
Upgrade
Change in Accounts Payable
11.639.383.123.651.64
Upgrade
Change in Other Net Operating Assets
-35.166.36-6.85-6.28-1.15
Upgrade
Operating Cash Flow
-157.78-107.29-103.73-60.91-40.4
Upgrade
Capital Expenditures
-1.92-1.82-1.83-1.25-1.55
Upgrade
Sale of Property, Plant & Equipment
--0.070.030.06
Upgrade
Investment in Securities
-288.21-103.9691.7-214.93-96.72
Upgrade
Investing Cash Flow
-290.13-105.7889.94-216.16-98.22
Upgrade
Short-Term Debt Issued
----2.96
Upgrade
Total Debt Issued
----2.96
Upgrade
Short-Term Debt Repaid
-----2.96
Upgrade
Total Debt Repaid
-----2.96
Upgrade
Issuance of Common Stock
441.45218.464.08272.37171.23
Upgrade
Financing Cash Flow
441.45218.464.08272.37171.23
Upgrade
Net Cash Flow
-6.465.39-9.71-4.6932.6
Upgrade
Free Cash Flow
-159.7-109.11-105.56-62.16-41.96
Upgrade
Free Cash Flow Margin
-2274.89%-1585.19%-4478.57%-1336.44%-565.60%
Upgrade
Free Cash Flow Per Share
-2.48-2.25-2.25-1.45-1.42
Upgrade
Levered Free Cash Flow
-91.67-46.7-58.03-29.71-22.62
Upgrade
Unlevered Free Cash Flow
-91.67-46.7-58.03-29.71-22.62
Upgrade
Change in Net Working Capital
5.25-16.997.77-2.74-2.07
Upgrade
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q